中国P站

Explainable artificial intelligence (XAI) in medical imaging; Deep learning interpretability in neuro-oncology; Transparent AI models for cancer diagnosis; Convolutional neural networks (CNN) in MRI analysis; AI-assisted brain cancer prognosis; Trustworthy AI in healthcare; Radiomics and explainable AI integration; Multimodal explainability in brain imaging

Introduction

Brain cancers, though relatively rare compared to other malignancies, represent some of the most aggressive and lethal tumors, particularly glioblastoma multiforme (GBM). Accurate and timely diagnosis plays a critical role in guiding treatment decisions, which may include surgery, radiation, and chemotherapy [1]. Magnetic resonance imaging (MRI) is the gold standard for non-invasive assessment of brain tumors, providing high-resolution images that capture tumor morphology, location, and progression [2]. In recent years, deep learning especially convolutional neural networks (CNNs) has shown remarkable success in analyzing MRI data to automate tumor detection, segmentation, classification, and grading [3]. Despite their high performance, these models suffer from a significant limitation: lack of interpretability. Most deep neural networks function as "black boxes," making predictions without providing human-understandable explanations [4]. This opacity poses a critical barrier to clinical adoption, where trust, accountability, and explainability are paramount. However, the adoption of DNNs in clinical neuro-oncology is hindered by their “black box” nature. Clinicians require transparent and interpretable AI models to trust and effectively integrate AI outputs into their diagnostic and treatment planning processes [5]. Explainable AI (XAI) addresses this critical need by developing methods to illuminate how and why models arrive at specific conclusions, translating complex computational processes into human-understandable insights [6].

Explainable AI (XAI) aims to enhance model transparency by providing visual, textual, or statistical justifications for algorithmic decisions [7]. In the context of brain cancer diagnosis, XAI techniques help radiologists and oncologists understand why a model classifies a particular MRI as malignant or benign, or why it identifies a tumor as high-grade versus low-grade [8]. This paper explores current XAI techniques applied to MRI-based brain tumor diagnosis, evaluates their utility in clinical decision support systems, and outlines future directions for trustworthy, explainable AI in neuro-oncology.

The role of deep learning in brain tumor diagnosis

Deep learning models have demonstrated impressive accuracy in brain tumor detection and classification. Architectures like U-Net, ResNet, DenseNet, and VGGNet are commonly used for tasks such as:

• Tumor segmentation, identifying tumor boundaries in MR images
• Classification, distinguishing between tumor types (e.g., glioma, meningioma, metastasis)
• Grading, differentiating high-grade from low-grade gliomas
• Survival prediction, estimating patient prognosis based on imaging and clinical data

These models typically require large, annotated datasets, such as the Brain Tumor Segmentation (BraTS) Challenge dataset, which provides multimodal MRI scans (T1, T1-Gd, T2, FLAIR) with expert-labeled tumor regions [9].

While performance metrics like accuracy, AUC, and F1-score validate model performance, they do not convey the reasoning behind the model’s predictions—an essential feature for clinical decision-making [10].

The clinical environment demands that AI systems be transparent, accountable, and aligned with human medical reasoning. Explainable AI is particularly crucial for several reasons:

• Trust—clinicians are more likely to use AI tools if they understand how decisions are made
• Validation—explanations allow cross-verification with human judgment and medical knowledge
• Regulation—legal and ethical standards (e.g., GDPR) require explainability in automated systems
• Error mitigation—interpretability helps identify biases, artifacts, and failure modes in model predictions

In the case of life-altering decisions like brain cancer diagnosis, explainable AI can act as a second opinion system, enhancing rather than replacing human expertise [11].

Challenges and limitations

Despite their promise, explainable AI systems face several hurdles:

• Different clinicians may interpret visual explanations differently
• Saliency maps highlight where the model is looking, but not why
• Some methods generate plausible but misleading justifications
• Some XAI methods are computationally intensive and unsuitable for real-time use
• No consensus exists on which XAI methods are best for clinical imaging

To mitigate these issues, future XAI systems must combine multiple explanation modalities, undergo rigorous clinical validation, and integrate seamlessly into radiology PACS systems and electronic health records. Approaches include hybrid models that combine imaging with genomic, histopathological, and clinical data for multimodal explainability, human-in-the-loop systems where clinicians can interact with AI explanations and refine model outputs, federated learning frameworks to train interpretable models across institutions while preserving data privacy, and regulatory frameworks from agencies like the FDA and EMA for certifying explainable AI tools in healthcare [12].

Conclusion

The use of explainable AI in brain cancer diagnosis represents a critical step toward the safe, ethical, and effective integration of AI into clinical practice. By interpreting deep neural network outputs in ways accessible to clinicians, XAI enhances trust, transparency, and decision-making accuracy. As deep learning models continue to improve in diagnostic performance, their utility will be limited unless paired with robust, validated explainability frameworks [13].

Future AI systems must prioritize not only accuracy but also interpretability, accountability, and usability in real-world healthcare environments. Only then can we fully realize the potential of AI as a trusted partner in the fight against brain cancer.